Glioblasztóma: ki dolgozik rajta

Intézményenként egy kártya. Célpontra vagy országra szűkítheted a listát.

• Minden célpont
• MGMT 20
• EGFR 14
• IDH 10
• STAT3 3
• TP53 0
• AKT 0
• mTOR 1
• PI3K 1
• PD-1 7
• ERK 0
• STING 0
• PD-L1 5
• YAP 0
• B7-H3 6
• MAPK 0
• PARP 1
• CTNNB1 0
• PTEN 1
• VEGF 5
• AMPK 0
• BRAF 1
• PRMT5 5
• TERT 3
• FGFR 1
• CDK4/6 0
• HDAC 0
• HIF-1 1
• IL-6 0
• NRF2 0
• PSMA 4
• MYC 2
• COX-2 0
• CXCR4 0
• EZH2 0
• CD47 0
• HER2 2
• JAK 0
• MEK 0
• MET 1
• METTL3 0
• TLR4 0
• ATM 2
• GPX4 0
• MDM2 0
• BCL-2 0
• CDKN2A 0
• CTLA-4 0
• FAK 0
• HSP90 0
• JNK 0
• MMP-9 1
• TNF 0
• CD19 0
• NF1 1
• NTRK 1
• TREM2 0
• ALK 2
• AR 0
• CD40 1
• HMGB1 0

1+ intézményből 1, a friss publikációk és a nyitott vizsgálatok szerint rendezve. Ez nem minőségi rangsor.

Funded research projects that name this disease in their title, terms or summary and have not ended yet: who is funded, where, how much and until when. Organisations only; the funder's page has the details.

• NIH NCI · R21

  Tackling tumor recurrence in pediatric brain tumors: identification of epigenetic memory and tumor microenvironment conducive to tumor recurrence in an inducible and reversible H3K27M murine model.

  University of Michigan at Ann Arbor· Ann Arbor, Egyesült Államok· 401 115 USD awarded in fiscal year 2026· until 2028. aug.

• NIH NINDS · R03

  Uncovering glycoRNA landscape in glioblastoma as a novel layer of immune evasion

  University of Texas Hlth Sci Ctr Houston· Houston, Egyesült Államok· 78 000 USD awarded in fiscal year 2026· until 2028. aug.

• NIH NCI · R42

  Targeting EGFR-Mutant NSCLC CNS Metastases with CM93, a Novel Brain-Penetrant EGFR Inhibitor

  Crimson Biopharm Inc· Brookline, Egyesült Államok· 1 125 000 USD awarded in fiscal year 2026· until 2028. aug.

• NIH NCI · F31

  Co-engineering CAR T cells and CAR macrophages with synthetic cytokine signaling for glioblastoma immunotherapy

  Stanford University· Stanford, Egyesült Államok· 50 114 USD awarded in fiscal year 2026· until 2029. szept.

• NIH NINDS · R21

  Regulation of Glioma Cell State Transition and Therapy Response by RNA Alternative Splicing

  Medical University of South Carolina· Charleston, Egyesült Államok· 188 750 USD awarded in fiscal year 2026· until 2028. aug.

• European Commission (Horizon Europe) · HORIZON-TMA-MSCA-PF-EF

  Investigating the role of tRNA-dependent translational control in the onset and progression of Glioblastoma. (tRansGlio)

  Institut National de la Sante Et de la Recherche Medicale· Paris, Franciaország· EU contribution 226 421 EUR· until 2029. aug.

• European Commission (Horizon Europe) · HORIZON-TMA-MSCA-PF-EF

  Investigating the mechanisms driving cancer cell DORMancy and REcurrence in glioblastoma (DORMIRE)

  Universite de Lausanne· Lausanne, Svájc· EU contribution 292 119 EUR· until 2029. aug.

• European Commission (Horizon Europe) · HORIZON-ERC

  ECLIPSE: Unveiling Brain Tumor Metabolism with Advanced In Vivo MRI

  Universitair Medisch Centrum Utrecht· Utrecht, Hollandia· EU contribution 2 099 257 EUR· until 2032. máj.

• European Commission (Horizon Europe) · HORIZON-ERC

  Spatiotemporal Mapping of Immune Cell Behavior in Glioblastoma (VideoTranscriptomics)

  Deutsches Krebsforschungszentrum Heidelberg· Heidelberg, Németország· EU contribution 1 484 173 EUR· until 2032. jan.

• European Commission (Horizon Europe) · HORIZON-TMA-MSCA-DN

  Training Europe’s Future Leaders in AI-driven Neuro-Oncology Diagnostics and Discovery (FutureMIND)

  Ruprecht-Karls-Universitaet Heidelberg· Heidelberg, Németország· EU contribution 4 379 817 EUR· until 2030. dec.· 8 countries

  The disease is named only in the funder's project summary, not in the title.

10 of 831 running projects, newest first. Listed amounts together: 406,7 M USD + 179,2 M EUR.

Sources: NIH RePORTER (U.S. National Institutes of Health, public domain) and CORDIS (European Commission, CC BY 4.0). Changes: filtered by disease, organisations matched to ROR.

Vizsgálatok, amelyek regiszteradata szerint az egyéni résztvevői adatokat (IPD) megosztják.

Ebben a nézetben egy vizsgálat sem jelzi, hogy megosztaná a résztvevői adatokat.

Publikációk erről a betegségről egy MeSH-módszerkifejezés szerint, például szekvenálási vagy képalkotó módszerre.

• Single-Cell Analysis 93
• Organoids 33
• Mendelian Randomization Analysis 14
• CRISPR-Cas Systems 11
• Gene Expression Profiling 151
• Sequence Analysis, RNA 10
• Exome Sequencing 2
• Proteomics 47
• Metabolomics 21
• Mass Spectrometry 9
• Flow Cytometry 16
• Immunohistochemistry 22
• Liquid Biopsy 10
• Circulating Tumor DNA 3
• Xenograft Model Antitumor Assays 226
• Positron-Emission Tomography 38
• Magnetic Resonance Imaging 234
• Machine Learning 266
• Deep Learning 43
• Cohort Studies 54
• Genome-Wide Association Study 13

• Assessing the Limit of Tumor Infiltration Detection Using Averaged Mass Spectra from a Handheld Picosecond Infrared Laser Mass Spectrometry Probe: A Proof-of-Principle Study.

  J Am Soc Mass Spectrom, 2026. nov.

• Uncovering the signaling networks of disseminated glioblastoma cells in vivo with INSIGHT.

  Nat Commun, 2026. aug.

• A Novel Peak-Shape Aware Approach for Mass Alignment in Mass Spectrometry.

  Rapid Commun Mass Spectrom, 2026. febr.

• Recent Development of the Probes for Fluorescence Spectroscopy, Mass Spectrometry and Electron Microscopy in Cancer Diagnosis.

  Protein Pept Lett, 2026. jan.

• PIPI-C: A Combinatorial Optimization Framework for Identifying Post-translational Modification Hot-spots in Mass Spectrometry Data.

  Mol Cell Proteomics, 2025. dec.

• Multimodal Mass Spectrometry Imaging with a Metal-Based Alignment Tool Enables Targeted Single-Cell Boronophenylalanine Uptake and Metabolic Profiling in Glioblastoma Tumors.

  Anal Chem, 2025. dec.

• A practical strategy enabling more reliable identification of ginsenosides from Panax quinquefolius flower by dimension-enhanced liquid chromatography/mass spectrometry and quantitative structure-retention relationship-based retention behavior prediction.

  J Chromatogr A, 2023. júl.

• Superior anticancer activity is demonstrated by total extract of Curcuma longa L. as opposed to individual curcuminoids separated by centrifugal partition chromatography.

  Phytother Res, 2018. jan.

• Distinct sulfonation activities in resveratrol-sensitive and resveratrol-insensitive human glioblastoma cells.

  FEBS J, 2012. máj.

Megmutatjuk, a betegség mely célpontjait említi az absztrakt, és onnan a rajtuk dolgozókhoz jutsz.